1 / 15

a WHO initiative to combat counterfeit medical products

a WHO initiative to combat counterfeit medical products. Dr V. Reggi - World Health Organization. WHO definition.

deron
Télécharger la présentation

a WHO initiative to combat counterfeit medical products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization

  2. WHO definition “a medicine, which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with the incorrect amount of active ingredients or with fake packaging”

  3. A counterfeit medical product is …. ……not a medical product! Arbitrary and unpredictable composition Manufactured evading regulatory control Manufactured and sold hiding its real origin Meant to deceive, unsafe

  4. A counterfeit medical product …. It is not primarily an IP issue! It is mainly a personal and public health problem! Medical products are not bags, CDs, watches or T-shirts! 2005: 3 women killed in Argentina by a counterfeit iron preparation 2006: 300+ people killed in Panama by mislabelled glycerine

  5. A counterfeit medical product …. … jeopardizes the credibility of health care delivery systems, pharmaceutical supply systems, … and governments!

  6. What is IMPACT ? IMPACT is a taskforce launched by WHO to gather all the most important international actors in the fight against the counterfeiting of medical products IMPACT aims at coordinating global action in order to promote and protect public health.

  7. “IMPACT approach”: collaboration among all those concerned is essential FAKE MEDICAL PRODUCTS

  8. IMPACT AFTER 1 YEAR • Secretariat: WHO • 5 working groups: • legislative and regulatory infrastructure • regulatory implementation • enforcement • technology • communication

  9. LEGISLATIVE & REGULATORY INFRASTRUCTURE http://www.who.int/entity/impact/events/FinalPrinciplesforLegislation.pdf

  10. ENFORCEMENT • Coordination of operations among participating countries • Internet monitoring and purchases • Training materials and manuals to improve skills of enforcement officers • Improve information exchange

  11. INTERPOL and WHO are strengthening their collaboration to support countries to combat counterfeit medical products

  12. ENFORCEMENT “ASEAN+China” Conference - November 2007, Jakarta 10 ASEAN Member Countries + China Drug regulatory authorities, police, customs, associations of health professionals, manufacturers, wholesalers, NGOs. Result: - launched the establishment of a SPOC-based network; - preparatory work for new coordinated operation (in the wake of Jupiter South-East Asia operation that lead to identifying source of counterfeit antimalarials)

  13. IMPACT toolkit • Experience from different countries; • Model legislation & regulations; • Training materials and methodologies; • Tools and manuals to assist national authorities in implementing activities; • Tools and methodologies for the assessment of national/regional situations.

  14. What can countries do? • Strengthen legislation ensuring a) counterfeiting medical products is a crime and b) punishment is commensurate to the consequences that it has on personal health and on the credibility of national health systems. • Strengthen regulatory oversight (including in so-called ‘free zones’) ensuring that all manufacturers, importers, exporters, distributors and retailers comply with the appropriate requirements that are necessary for a secure distribution chain. • Improve collaboration among governmental entities (such as health, police, customs, local administrative units, judiciary), private sector and civil society in order to effectively combat counterfeiters. • Develop a communication strategy to ensure that health professionals, the general public and the media are aware of the dangers associated with counterfeit medicines.

  15. Thank you www.who.int/impact

More Related